Escitalopram for the treatment of depression and anxiety disorder
Authors:
R. Honzák
Authors‘ workplace:
Ústav všeobecného lékařství 1. LF UK, Praha
přednosta MUDr. B. Seifert
; Psychiatrická ambulance IKEM, ředitel prof. ing. R. Poledne, CSc.
; Psychiatrická katedra IPVZ, vedoucí prof MUDr. K. Chromý, CSc.
Published in:
Prakt. Lék. 2005; 85(11): 641-645
Category:
Therapy
Overview
Because major depression and anxiety disorders have negative effects on the patient’s quality of life as well as on other disease states, proper recognition and treatment of depression and pathologic anxiety are important in primary care setting. The submitted article sumarizes pharmacological characteristics and clinical efficacy of the latest selective serotonin inhibitor, escitalopram, which is the first pure antidepressant stereoisomer in clinical use. Escitalopram is effective across different diagnoses in the group of mood and anxiety disorders: major depression, panic disorder, obsessive-compulsive disorder, general anxiety disorder, social phobia, and premenstrual dysphoric disorder. Escitalopram is well tolerated in the short- and in longterm treatment.
Key words:
antidepressants – SSRI – escitalopram – treatment – major depression – anxiety disorders.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2005 Issue 11
Most read in this issue
- Quality of life – defining the concept and its significance for medicine and health care
- Essential hypertension – a review
- Treatment and clinical manifesta- tions of primary intraocular lymphoma
- Risk factors and prevalence of bad posture in school-age children